Access to anti-retroviral drugs, female in Latvia

Latvia: Access to anti-retroviral drugs, female was 54.0% in 2024. ◆ Volatile

Latest (2024)
54.0%
Change on year
up 1.9%
World rank
114th
of 141 countries
All-time high
54.0%
in 2024
All-time low
1.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Latvia, 2000–2024

02040602000201220242000: 1 %2001: 1 %2002: 1 %2003: 2 %2004: 2 %2005: 2 %2006: 2 %2007: 4 %2008: 4 %2009: 6 %2010: 7 %2011: 8 %2012: 9 %2013: 10 %2014: 11 %2015: 13 %2016: 27 %2017: 33 %2018: 39 %2019: 47 %2020: 47 %2021: 50 %2022: 52 %2023: 53 %2024: 54 %

Source: UNAIDS estimates. Measured in %.

Analysis

Latvia recorded 54.0% for access to anti-retroviral drugs, female in 2024. That is the highest value across all 25 years on record.

Compared with earlier readings it is up 1.9% on the previous year and up 390.9% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Latvia peaked at 54.0% in 2024 and was at its lowest, 1.0%, in 2000.

That places Latvia 114th out of 141 countries with data for 2024, putting it in the bottom quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Latvia, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Latvia, 2000 to 2024.
Year % Change
2000 1.0%
2001 1.0% +0.0%
2002 1.0% +0.0%
2003 2.0% +100.0%
2004 2.0% +0.0%
2005 2.0% +0.0%
2006 2.0% +0.0%
2007 4.0% +100.0%
2008 4.0% +0.0%
2009 6.0% +50.0%
2010 7.0% +16.7%
2011 8.0% +14.3%
2012 9.0% +12.5%
2013 10.0% +11.1%
2014 11.0% +10.0%
2015 13.0% +18.2%
2016 27.0% +107.7%
2017 33.0% +22.2%
2018 39.0% +18.2%
2019 47.0% +20.5%
2020 47.0% +0.0%
2021 50.0% +6.4%
2022 52.0% +4.0%
2023 53.0% +1.9%
2024 54.0% +1.9%

Averages by decade

DecadeAverage LowestHighest Years
2000s 2.5% 1.0% 6.0% 10
2010s 20.4% 7.0% 47.0% 10
2020s 51.2% 47.0% 54.0% 5

Countries ranked near Latvia

  1. 111 Gambia 55.0% compare
  2. 111 Panama 55.0% compare
  3. 111 Paraguay 55.0% compare
  4. 114 Venezuela, Bolivarian Republic of 54.0% compare
  5. 116 Armenia 52.0% compare
  6. 116 Libya 52.0% compare

See the full ranking of 160 places →

More gender data for Latvia

All data for Latvia →

Frequently asked questions

What is access to anti-retroviral drugs, female in Latvia?
Access to anti-retroviral drugs, female in Latvia was 54.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Latvia?
The highest recorded value was 54.0% in 2024.
What is the lowest access to anti-retroviral drugs, female recorded in Latvia?
The lowest recorded value was 1.0% in 2000.
How does Latvia rank for access to anti-retroviral drugs, female?
Latvia ranks 114th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Latvia?
Over the last ten years it is up 390.9%. The long-run trend across the full record is volatile.
Where does this Latvia data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Latvia. Statizoid, drawing on UNAIDS estimates. Retrieved 08 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/latvia/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/latvia/">Access to anti-retroviral drugs, female in Latvia</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.